Chemokine receptor type 6 (CCR6)+CD4+ T cells are preferentially infected and depleted during HIV disease progression, but are preserved in non-progressors. CCR6 is expressed on a heterogeneous population of memory CD4+ T cells that are critical to mucosal immunity. Preferential infection of these cells is associated, in part, with high surface expression of CCR5, CXCR4, and α4β7. In addition, CCR6+CD4+ T cells harbor elevated levels of integrated viral DNA and high levels of proliferation markers. We have previously shown that the CCR6 ligands MIP-3α and human beta defensins inhibit HIV replication. The inhibition required CCR6 and the induction of APOBEC3G. Here, we further characterize the induction of apolipoprotein B mRNA editing enzyme (APOBEC3G) by human beta defensin 2. Human beta defensin 2 rapidly induces transcriptional induction of APOBEC3G that involves extracellular signal-regulated kinases 1/2 (ERK1/2) activation and the transcription factors NFATc2, NFATc1, and IRF4. We demonstrate that human beta defensin 2 selectively protects primary CCR6+CD4+ T cells infected with HIV-1. The selective protection of CCR6+CD4+ T cell subsets may be critical in maintaining mucosal immune function and preventing disease progression.
CD4+ CCR6+ T cells are highly susceptible to HIV infection, and a high cytokine producing CCR6+ T cell subset is selectively lost during HIV infection. The CCR6 chemokine MIP-3α (CCL20) is produced at sites of infection in SIV animal models. Recently, we have shown that MIP-3α inhibits HIV replication. This inhibition of HIV infection is mediated by CCR6 signaling and eventuates in increased APOBEC3G expression. Since there are few existing reports on the role of MIP-3α in health or disease, we studied its production by PBMCs from HIV-seronegative and HIV+ subjects. We evaluated the ability of PBMCs to produce MIP-3α in response to antigen stimulation using cells obtained from two groups: one composed of HIV-seronegative subjects (n = 16) and the other composed of HIV+ subjects (n = 58), some asymptomatic and some with clinically defined AIDS. Antigens included fragment C of the tetanus toxin, Candida albicans, whole-inactivated HIV, and HIV p24. MIP-3α was detected by ELISA in tissue culture supernatants of antigen-stimulated PBMCs. MIP-3α production by antigen-stimulated PBMCs was readily measured for HIV-negative subjects and for HIV-seropositive asymptomatic subjects, but not for patients with AIDS. These results suggest that subversion of the MIP-3α-CCR6 axis by HIV during the course of infection contributes to the loss of immune function that eventually leads to AIDS.
1 March 2017 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Th17 cells (i.e., IL17-producing T cells) are selectively depleted in acute HIV infection and in pathogenic, but not in non-pathogenic, SIV infection. Since IL17 stimulates the production of antimicrobial peptides including defensins and contributes to the preservation of mucosal integrity, Th17 cell loss initiates a vicious cycle of increased mucosal permeability, microbial translocation, and inflammation that further fuels HIV infection and immune activation, contributing to HIV pathogenesis. Our studies demonstrate that Th17 cells are more permissive to HIV infection than non-IL17 secreting cells. Compared to activated, IFN-γ secreting T cells, Th17 cells are more likely to get infected and express higher levels of HIV p24, even when HIV pseudotyped with AMLV envelope is used to infect cells, indicating that the increase in infection is not due to variations in HIV receptor expression. CCR6, a chemokine receptor expressed on Th17, cells further defines a subset of activated cells that is highly susceptible to HIV infection. Using RNA microarray technology, we determined that Th0 CCR6-cells express higher levels of RNASEs 2, 3 and 6 than Th17 CCR6+ cells. We also found that these RNASEs were more effective in inhibiting HIV in Th17 than Th0 cells, indicating that they may play a key role in reducing infection in Th0 cells. These findings point at future directions for prevention and treatment of HIV infection. First, since we characterized that beta-defensin 2 inhibits HIV infection in CCR6+ cells bi inducing expression of APOBEC3G, the defensin itself or small molecule derivatives could be used to prevent loss of Th17 cells that express CCR6. Second, the elucidation of the mechanism of activity of RNASEs could help protecting highly permissive TH17 cells. Third, pathways leading to T cell activation and Th17 differentiation could be targeted to decrease cells permissivity and lower immune activation.